Lost Money on Humacyte, Inc.(HUMA)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire • 10/29/24
Levi & Korsinsky Reminds Shareholders of an Investigation into Humacyte, Inc. (HUMA) Regarding Potential Securities Fraud AllegationsAccesswire • 10/28/24
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024GlobeNewsWire • 10/28/24
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA)Business Wire • 10/23/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of InvestorsBusiness Wire • 10/23/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of InvestorsBusiness Wire • 10/23/24
The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of InvestorsBusiness Wire • 10/22/24
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024GlobeNewsWire • 10/08/24
Humacyte, Inc. (HUMA) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 09/26/24
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024GlobeNewsWire • 09/26/24
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To ReviewBenzinga • 08/12/24
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular TraumaGlobeNewsWire • 08/09/24
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for HemodialysisGlobeNewsWire • 07/31/24
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony JonesGlobeNewsWire • 07/16/24
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCsBusiness Wire • 07/09/24